# Safety Study of GC1008 in Patients With Focal Segmental Glomerulosclerosis (FSGS) of Single Doses of GC1008 in Patients With Treatment Resistant Idiopathic FSGS

> **NCT00464321** · PHASE1 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 16 (actual)

## Conditions studied

- Focal Segmental Glomerulosclerosis

## Interventions

- **BIOLOGICAL:** GC1008
- **BIOLOGICAL:** GC1008
- **BIOLOGICAL:** GC1008
- **BIOLOGICAL:** GC1008

## Key facts

- **NCT ID:** NCT00464321
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05
- **Primary completion:** 2010-01
- **Final completion:** 2010-02
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2014-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00464321

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00464321, "Safety Study of GC1008 in Patients With Focal Segmental Glomerulosclerosis (FSGS) of Single Doses of GC1008 in Patients With Treatment Resistant Idiopathic FSGS". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00464321. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*